{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032104","form_type":"8-K","ticker":"CDT","cik":"0001896212","company_name":"CDT Equity Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.942221+00:00","generated_at":"2026-06-21T21:33:35.327519+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Murphy Canyon SPAC to merge with Conduit Pharmaceuticals at $650M enterprise value","bullets":["Deal consideration $650 million payable in 65 million MURF shares valued at $10.00 each.","Conduit shareholders to receive MURF Class A common stock; MURF to rename 'Conduit Pharmaceuticals Inc.'","PIPE of $27 million from private investor at $10.00/unit, each unit one share plus one warrant.","Closing expected Q1 2023 subject to stockholder approvals and minimum $27M cash condition.","Sponsor support agreement secured; lock-up agreements for certain Conduit shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032104","json":"https://secwatch.observer/filing/0001493152-22-032104.json","markdown":"https://secwatch.observer/filing/0001493152-22-032104.md","text":"https://secwatch.observer/filing/0001493152-22-032104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315222032104/0001493152-22-032104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315222032104/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:33:35.327519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ef1cd4dc24940cd99a0f0db5106e409669a4766c","claim":"CDT Equity Inc. entered into Merger Agreement with Murphy Canyon Acquisition Corp., Conduit Pharmaceuticals Limited, and Conduit Merger Sub, Inc. valued at $650,000,000 (effective 2022-11-08).","evidence_excerpt":"On November 8, 2022, Murphy Canyon Acquisition Corp., a Delaware corporation (“ MURF ”), entered into an agreement and plan of merger (the “ Merger Agreement ”) by and among MURF, Conduit Pharmaceuticals Limited, a Cayman Islands exempted company (“ Conduit ”) and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of MURF (“ Merger Sub ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315222032104/0001493152-22-032104-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Murphy Canyon Acquisition Corp., Conduit Pharmaceuticals Limited, and Conduit Merger Sub, Inc."},{"label":"Value","value":"$650,000,000"},{"label":"Effective","value":"2022-11-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}